This system defines about 50 genomic tests with sufficient evidence for clinical implementation (e.g., KRAS and human epidermal growth factor receptor 2 (HER2) tests to inform use of cetuximab in colorectal cancer and lapatinib in breast cancer, respectively). The gene discussed is KRAS; the disease is colorectal cancer.